When patients undergo continuous renal replacement therapy (CRRT), they need anticoagulants to keep the equipment running smoothly. Doctors often choose between citrate and nafamostat mesylate. Because some patients have a high risk of bleeding, finding a safe way to prevent blood from clotting in the machine is vital.
A large review of 2,247 patient episodes compared these two treatments. The results showed that both options were equally effective at keeping filters clear and preventing clots. However, the data suggested that nafamostat mesylate was associated with a lower risk of bleeding events overall. This trend was especially noticeable in patients who were already at high risk for bleeding or those receiving low doses of the medication.
While these findings are encouraging for patients who cannot safely use citrate, it is important to note that the quality of evidence is currently low to very low. Because the data comes from a collection of different studies rather than one large, high-quality trial, more research is needed to confirm these results before it can be used as a standard rule.
